1. Coherus BioSciences I. Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh). https://investors.coherus.com/news-releases/news-release-details/coherus-announces-us-fda-approval-yusimrytm-adalimumab-aqvh. Accessed 23 May 2023.
2. Coherus BioSciences, Inc. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761216s003lbl.pdf#page=40. Accessed 23 May 2023.
3. AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125057. Accessed 23 May 2023.
4. Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther. 2006;6:1349–1360. http://www.ncbi.nlm.nih.gov/pubmed/17223742.
5. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22:2719. https://doi.org/10.3390/ijms22052719.